Business Context and Reporting Period
This Form 8-K, dated October 21, 1998, reports E. I. du Pont de Nemours and Company's (DuPont) third-quarter 1998 earnings. The filing highlights a strategic shift in reporting due to the planned divestiture of its petroleum business, Conoco, which is now classified as discontinued operations. The company also completed the acquisition of Merck & Co.'s interest in The DuPont Merck Pharmaceutical Company and initiated significant productivity improvement measures.
Key Financial Metrics
Revenue: Third-quarter sales from continuing operations were $6.04 billion, a 7% increase year-over-year (excluding divested businesses). Year-to-date sales totaled $18.67 billion, up 3%.
Profitability: Reported net loss for the quarter was $605 million ($0.54 per share diluted), driven by nonrecurring charges. Underlying earnings (excluding nonrecurring items) were $610 million ($0.67 per share diluted), down from $725 million ($0.85 per share) in the prior year.
Cash Flow and Liquidity: The filing does not provide specific cash flow statement data or liquidity ratios. However, the company executed a debt call and tender offer to retire $1.633 billion of high-interest debt.
Debt: DuPont retired $1.633 billion in long-term debt during the quarter, incurring an extraordinary after-tax charge of $201 million.
Margins: Income from continuing operations before nonrecurring items was $610 million. Reported income from continuing operations before the extraordinary item was a loss of $564 million.
Material Changes Versus Prior Period
- Earnings Decline: Underlying diluted earnings per share fell from $0.85 in Q3 1997 to $0.67 in Q3 1998. Reported earnings swung from a $0.02 loss in Q3 1997 to a $0.54 loss in Q3 1998.
- Nonrecurring Charges: The quarter included significant charges: $1.3 billion for in-process R&D write-offs (primarily from the Merck acquisition), $391 million for productivity initiatives (including 2,600 employee separations), and $201 million for debt extinguishment.
- Segment Performance:
- Chemicals: Earnings rose 6% to $161 million; sales fell 4% due to volume declines.
- Fibers: Earnings dropped 12% to $207 million due to lower "Dacron" polyester volumes and prices.
- Life Sciences: Earnings plummeted 60% to $48 million due to lower agricultural sales, bad debt in emerging markets, and pharmaceutical launch costs.
- Discontinued Operations (Conoco): Income fell to $160 million from $256 million, impacted by a 32% drop in realized oil prices.
Guidance, Outlook, and Risks
Management Commentary: CEO Charles O. Holliday, Jr. attributed the earnings decline to weakening global economies, lower oil prices, and a strong U.S. dollar. Management emphasized a continued focus on productivity, cost reduction, and asset rationalization to navigate the challenging 1999 economic outlook.
Strategic Actions:
- Announced the fourth-quarter IPO of Conoco, followed by a planned split-off of remaining shares to DuPont shareholders.
- Planned sale of remaining coal operations in the fourth quarter.
- Implementation of company-wide productivity initiatives, including personnel reductions.
Risks and Contingencies:
- Market Conditions: Exposure to volatile oil and gas prices and global economic slowdowns.
- Acquisition Integration: Significant charges related to the Merck acquisition and in-process R&D valuations, which are subject to revision upon final appraisal.
- Divestiture Execution: Risks associated with the timing and terms of the Conoco IPO and split-off.
Investor Verification Checklist
- Verify the final valuation of in-process R&D for the Merck acquisition, as the $1.3 billion charge is based on preliminary allocations.
- Monitor the progress and pricing of the Conoco IPO and the subsequent split-off transaction.
- Assess the impact of the 2,600 employee separations on future operating costs and productivity gains.
- Review the trajectory of oil prices and their effect on the remaining petroleum assets prior to full divestiture.
- Confirm the timeline for the sale of coal operations and the associated financial impact.